PT - JOURNAL ARTICLE AU - Ouanes, Yassine AU - Bibi, Mokhtar AU - Baradai, Nesrine AU - Boukhris, Marouane AU - Chaker, Kays AU - Kacem, Aziz AU - Hedhli, Houcem AU - Deli, Kheireddine Mrad AU - Sellami, Ahmed AU - Rhouma, Sami Ben AU - Nouira, Yassine TI - Does BCG protect against SARS-CoV-2 infection ?: elements of proof AID - 10.1101/2020.05.01.20087437 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.01.20087437 4099 - http://medrxiv.org/content/early/2020/05/06/2020.05.01.20087437.short 4100 - http://medrxiv.org/content/early/2020/05/06/2020.05.01.20087437.full AB - Background There are several factors explaining the difference in the spread of SARS-CoV-2 infection including the BCG vaccination. This fact is supported by the concept of beneficial non specific effect of this live vaccine associated to its interaction with the immune system.Our study aims to identify the correlation between the universal BCG vaccination policy and the mortality attributed to COVID-19.Methods We conducted an epidemiological study in which we collected COVID-19 pandemic data of April 11th, 2020 from the web site worldometers.info. The exclusion criteria for our study were a number of inhabitants less than one million, low-income countries according to the World Bank classification, a total number of infection cases less than 500 and countries that have performed less than one hundred tests per million inhabitants.Results Countries that never had universal BCG vaccination policy have a higher mortality (correlated to performed diagnostic tests) attributed to SARS-CoV-2 infection (p<0.001).We found that the year of introduction of vaccination influenced significantly the mortality. Countries that started immunization policy before 1960 had more favorable results (p=0.049).For countries that started the BCG vaccination after 1960, countries with current policies have lower mortality attributed to SARS-CoV-2 infection than countries that have stopped immunization (p=0.047).Conclusions Countries that have a BCG vaccination policy have a lower mortality attributed to SARS-CoV-2 infection. The populations of countries that applied this immunization before 1960 are more protected even if this universal policy has been interrupted.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available from the corresponding author.